U.S. FDA Action On Sun Pharma Plant Problems With All Sun Data
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA is expected to expand its investigation of Sun Pharmaceutical Industries and its production plant in Gujarat recently presented with a warning letter.